Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00287222
Recruitment Status : Completed
First Posted : February 6, 2006
Results First Posted : July 15, 2011
Last Update Posted : July 15, 2011
Genentech, Inc.
Information provided by:
University of Arkansas

February 3, 2006
February 6, 2006
March 22, 2011
July 15, 2011
July 15, 2011
February 2006
September 2010   (Final data collection date for primary outcome measure)
Number of Participants Who Remained Free of Progression at the 27th Week. [ Time Frame: 27 weeks ]
The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment.
Complete list of historical versions of study NCT00287222 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment. Secondary objectives include the subject's time in weeks from treatment onset to documented disease progression as assessed by the RECIST criteria, response rate, median and overall survival, safety and tolerability.
This is a phase II study to assess the proportion of subjects that remain progression-free by the 27th week following the onset of treatment and to assess the efficacy of the combination of Bevacizumab and Erlotinib in prolonging time to progression in subjects with inoperable and metastatic hepatocellular carcinoma. Subjects will be treated with a combination of rhuMAb VEGF (Bevacizumab), in combination with Erlotinib and TTP will be assessed as per RECIST criteria. The disease will be evaluated at base line and every 9 weeks with CT scan/MRI and AFP levels. Subjects will be kept on the study till disease progression (as defined by RECIST criteria) or death.
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hepatocellular Carcinoma
  • Drug: Bevacizumab
    15 mg/KG I.V. every 21 days
    Other Name: Avastin
  • Drug: Erlotinib
    150 mg orally every day
    Other Name: Tarceva
Experimental: 1 - Bevacizumab/Erlotinib
Subjects will be treated with bevacizumab and erlotinib
  • Drug: Bevacizumab
  • Drug: Erlotinib
Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol. 2013 Jun;36(3):254-7. doi: 10.1097/COC.0b013e318248d83f.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects should have histologically or cytologically confirmed diagnosis of hepatocellular carcinoma, regardless of biopsy site.
  • Subjects with a liver mass and markedly elevated AFP (>500ng/mL) are eligible.
  • Subjects should not be on the liver transplantation schedule
  • Subjects can have prior therapy with sorafenib (nexavar) only if the therapy was stopped due to toxicity or allergic reaction soon after starting. Subjects must have been treated for less than two weeks to be eligible.
  • Radiation therapy for palliation to the areas outside the site of tumor used for measurements is permitted. If a subject has received radiation therapy to the liver, the subject id eligible if there is a new lesion or if the prior lesion has increased in size.
  • Subjects who have recovered from prior surgical procedure
  • Performance status of ECOG 0-2
  • Measurable or evaluable disease
  • Be declared unresectable or not suitable candidates for surgery
  • Adequate organ functions
  • Serum bilirubin <3 mg/dl, AST <5x ULN, ALT <5XULN
  • Serum albumin >2.5 g/dl
  • Serum creatinine < 2.0 mg/dl
  • ANC >1200 MM3
  • Platelet count >75,000/ml
  • PT/INR < 1.5 X ULN
  • Life expectancy of >3 months
  • Subjects should be able to sign informed consent and be agreeing to comply with therapy and follow up.
  • Negative pregnancy test in women with childbearing potential, within one week prior to initiation of treatment.
  • Fertile men and women must agree to use adequate contraception prior to study entry, for the duration of study participation, and for at least 1 week after therapy.
  • Age >/= 18 years. The agents Bevacizumab and Erlotinib have not been studied in pediatric subjects, thus the doses to be used in this study cannot be assumed to be safe in children.

Exclusion Criteria:

  • Surgically resectable disease
  • Subjects with active bacterial infections
  • Subjects with brain metastases
  • Pregnant women (positive pregnancy test) or lactating
  • No other malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the subject has been disease-free for five years.
  • Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sjogren's syndrome) or congenital abnormality (e.g. Fuch's dystrophy).
  • Current, recent (within 4 weeks of the first infusion of the study), or planned participation in an experimental drug study other than a Genentech-sponsored Bevacizumab/Erlotinib cancer study
  • Hepatic encephelopathy (as per treating physician's evaluation)
  • Uncontrolled blood Pressure >150/100 mmHg
  • Unstable angina
  • NYHA grade II or greater congestive heart failure
  • History or myocardial infraction within 6 months
  • History of stroke within 6 months
  • Clinically significant peripheral vascular disease (clinically significant venous or arterial thrombotic disease).
  • Evidence of bleeding diathesis or coagulopathy
  • Urine protein: creatinine ratio >1.0 at screening
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
  • Serious, non-healing wound, ulcer, or bone fracture
  • Inability to comply with study and/or follow-up procedures
  • Gastrointestinal disease resulting in an inability to take oral medication or a requirement for intravenous hyperalimentation.
  • History of significant gastrointestinal bleeding requiring procedural intervention (e.g. variceal banding, TIPS procedure, arterial embolization, topical coagulation therapy) within six months prior to study Day 0.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
  • Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
UARK 2005-13
Not Provided
Not Provided
Rangaswamy Govindarajan, UAMS
University of Arkansas
Genentech, Inc.
Principal Investigator: Rangaswamy Govindarajan, MD University of Arkansas
University of Arkansas
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP